Prime Medicine Announces Pricing of Upsized Initial Public Offering
businesswire.com
news
2022-10-20 00:00:00

October 19, 2022 09:47 PM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Prime Medicine. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.
